{"id":"W2896903565","doi":"10.1093/annonc/mdy283.083","title":"Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Randomization; Adverse effect; Intention-to-treat analysis; Randomized controlled trial; Surgery; Ipilimumab; Interim analysis; Gastroenterology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00300925,0.0003339094,0.0009034033,0.0005377339,0.0002113605,0.000649796,0.0004836367,0.000476844,0.001253005],"category_scores_gemma":[0.003099749,0.0001658095,0.002023085,0.000489132,0.0002409296,0.00041989,0.0003179944,0.0009363283,0.0001193124],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009206604,"about_ca_system_score_gemma":0.0005739554,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008930023,"about_ca_topic_score_gemma":0.001337455,"domain_scores_codex":[0.9992193,0.0003066064,0.00008156399,0.000163986,0.0001263888,0.0001021355],"domain_scores_gemma":[0.9959134,0.001396983,0.001876215,0.000206381,0.0001279173,0.0004791488],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3290347,0.001548327,0.5764111,0.0007651772,0.005748664,0.0003317257,0.0001559217,0.004934575,0.005735591,0.0002233352,0.001779313,0.07333153],"study_design_scores_gemma":[0.01283267,0.05769031,0.9085096,0.0001049237,0.006104597,0.000816172,0.00008378677,0.007350668,0.002705835,0.000286626,0.003463798,0.00005093186],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967204,0.001382448,0.0003005265,0.00004889402,0.00001491101,0.0000807167,0.0009354631,0.00001125129,0.0005055161],"genre_scores_gemma":[0.9982277,0.000216793,0.0001356842,0.00005685721,0.00003021413,0.00006713271,0.001052712,0.000004345681,0.0002086605],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00300925,"threshold_uncertainty_score":0.01591462,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0451959082111775,"score_gpt":0.3442911102088804,"score_spread":0.2990952019977029,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}